Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD, food-effect and DDI study of BPN14770 in healthy volunteers
jRCT2031200182Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zatolmilast (5 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Safety endpoints, Pharmacokinetics of BPN14770 and 2 more. Started Nov 2020; status: completed.
02
Drugs
zatolmilast
Beyond the preview
Go deeper on jRCT2031200182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200182.